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reproduction in any medium, provided the original work iTuberculosis, a global threat to public health, is becoming untreatable due to
widespread drug resistance to frontline drugs such as the InhA-inhibitor iso-
niazid. Historically, by inhibiting highly vulnerable targets, natural products have
been an important source of antibiotics including potent anti-tuberculosis
agents. Here, we describe pyridomycin, a compound produced by Dactylospor-
angium fulvum with specific cidal activity against mycobacteria. By selecting
pyridomycin-resistant mutants of Mycobacterium tuberculosis, whole-genome
sequencing and genetic validation, we identified the NADH-dependent enoyl-
(Acyl-Carrier-Protein) reductase InhA as the principal target and demonstrate
that pyridomycin inhibits mycolic acid synthesis in M. tuberculosis. Furthermore,
biochemical and structural studies show that pyridomycin inhibits InhA directly
as a competitive inhibitor of the NADH-binding site, thereby identifying a new,
druggable pocket in InhA. Importantly, the most frequently encountered iso-
niazid-resistant clinical isolates remain fully susceptible to pyridomycin, thus
opening new avenues for drug development.INTRODUCTION Natural products have long provided a rich source of effectiveToday, infection with Mycobacterium tuberculosis accounts for
up to two million deaths annually (Glaziou et al, 2009). Major
confounding factors such as poverty, homelessness and the
prevalence of HIV/AIDS (Harrington, 2010) mean that tubercu-
losis will indefinitely remain an important cause of morbidity
and mortality throughout the world. Furthermore, despite the
small, but growing number of drugs that are effective at killing
M. tuberculosis, the current treatment is still burdened by its
duration (typically 6 months for drug-sensitive strains) and
the ever increasing number of multidrug (MDR) and extensively
drug resistant (XDR) clinical isolates of M. tuberculosis
(Cegielski, 2010). Together, this underlines the need for
alternative therapeutic entities that can be used both to shorten
the duration of therapy and to combat the growing problem of
clinical drug resistance.al Health Institute,
itut fu¨r Pharmazeu-
nd
41 21 693 1790;
Ltd on behalf of EMBO. This
ercial License, which perm
s properly cited.anti-tuberculosis agents. Themost active of these in current use,
the rifamycins (rifampicin, rifabutin and rifapentine), inhibit
RNA polymerase and are crucial for front-line treatment of the
disease. Furthermore, several other natural products such as
the aminoglycosides (streptomycin, amikacin and kanamycin)
and the peptide antibiotic (capreomycin) are part of the current
portfolio of anti-tuberculosis drugs. The rich diversity of natural
products represents a powerful tool for drug discovery, firstly,
in the form of leads for potential anti-microbial agents and
secondly, as a means of identifying those targets that are most
vulnerable in the bacterium.
In 1953, pyridomycin was first described as an antibiotic
that exhibited specific activity against different mycobacteria
including M. tuberculosis and M. smegmatis (Maeda et al,
1953). Pyridomycin (Fig 1A) is produced by Streptomyces
pyridomyceticus (Maeda et al, 1953; Yagishita, 1954, 1955,
1957a,b) or Dactylosporangium fulvum (Shomura et al, 1986).
Its biosynthesis was first studied in 1968 (Ogawara et al, 1968)
and more recently in 2011 (Huang et al, 2011) when the
involvement of both non-ribosomal peptide synthetases (NRPS)
and polyketide synthases (PKS) was proposed. Despite this
body of work, the mechanism of action of pyridomycin
against M. tuberculosis is unknown, and its potential as an
anti-tuberculosis compound has not been assessed.is an open access article under
its use, distribution and
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Figure 1. Chemical structure and intracellular activity of pyridomycin.
A. Chemical structure of pyridomycin.
B. The activity of pyridomycin on intracellular M. tuberculosis was tested in activated THP-1-derived macrophages. Cells were infected at an MOI of 1:1
with M. tuberculosis Erdman and treated with isoniazid (INH) at 1mg/ml, rifampicin (RIF) at 1mg/ml, streptomycin (STR) at 10mg/ml or pyridomycin (PYR)
at 10mg/ml. Colony forming units (CFU) were determined after 7 days exposure to drugs. NT refers to the untreated sample and NT0 to untreated sample
at time 0. The experiment was performed in duplicate and results are shown as mean values and standard errors.The aim of this study was to determine how pyridomycin
kills M. tuberculosis and to identify its target. To achieve this,
a combination of approaches involving resistance mapping,
genetic validation, biochemistry, enzyme inhibition and X-ray
crystallographic analysis of the target are described. The
combined results unambiguously indicate that pyridomycin is
a competitive inhibitor of the NADH-binding site of InhA,
NADH-dependent enoyl-[Acyl-Carrier-Protein] reductase, the
target of the two anti-tuberculosis pro-drugs isoniazid and
ethionamide (Banerjee et al, 1994; Vilcheze et al, 2006).RESULTS
Purification of pyridomycin
Several strains of Streptomyces pyridomyceticus (NRRL B-2517,
ISP-5024 and DSM40024) were initially tested for pyridomycin
production with limited success, likely due to the presence of
producing and non-producing populations in the same culture.
Pyridomycin (Fig 1A) was, however, readily produced by and
purified from Dactylosporangium fulvum (NRRL B-16292) with
a yield of 20–40mg/L at a purity >99% and with an NMR
spectrum as previously reported (Kinoshita et al, 1989).
Anti-bacterial properties of pyridomycin
Pyridomycin has been described to act specifically against
mycobacteria, with little or no activity against other Gram-
positive and Gram-negative species (Maeda et al, 1953).
In order to verify its spectrum of activity, the resazurin
reduction microplate assay (REMA) was used to determine
the minimum inhibitory concentration (MIC) for various
bacteria. From Table 1, it can be clearly seen that pyridomycinEMBO Mol Med (2012) 4, 1032–1042 is effective against all members of the Mycobacterium genus
tested including M. tuberculosis (strain H37Rv, MIC¼ 0.31–
0.63mg/ml) and M. smegmatis (strain mc2 155, MIC¼ 0.62–
1.25mg/ml). Pyridomycin, however, showed no detectable
activity against other bacteria, including the close relative
C. glutamicum (all MIC> 100mg/ml). These data therefore
agree with earlier observations (Maeda et al, 1953; Maeda,
1957) and suggest that pyridomycin targets a mycobacterial
component that is either sufficiently divergent or absent in
other genera.
To further understand the properties of pyridomycin against
M. tuberculosis, its minimum bactericidal concentration (MBC)
was determined and its activity against non-replicating and
intracellularM. tuberculosismeasured. MBC data demonstrated
that pyridomycin is bactericidal against M. tuberculosis H37Rv
at concentrations of 0.62–1.25mg/ml. Evaluation of pyrido-
mycin activity against non-replicating M. tuberculosis using
the streptomycin-starved 18b (ss18b) model (Sala et al, 2010)
revealed that pyridomycin is not effective, thereby implying that
it may target a function involved in active growth. Finally,
the intracellular killing activity of pyridomycin was assessed
ex vivo after infection of activated THP1-derived macrophages.
The results indicated that, when left untreated for a 7-day
period, intracellular M. tuberculosis grew by at least 3 logs,
whilst exposure to both pyridomycin (10mg/ml) and
rifampicin (1mg/ml) prevented any multiplication within the
macrophages (Fig 1B). Further controls showed that strepto-
mycin (10mg/ml) had no impact on the growth of intracellular
bacteria while isoniazid (1mg/ml) was able to reduce the
intracellularM. tuberculosis load by 1 log (Fig 1B). Pyridomycin
is therefore clearly able to enter macrophages and arrest
bacterial replication.2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1033
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Table 1. Bacterial susceptibility to pyridomycin as measured by resazurin
reduction microtitre assay
Bacterium Pyridomycin MIC (mg/ml)
Mycobacterium tuberculosis 0.39
Mycobacterium bovis BCG 0.39
Mycobacterium smegmatis 0.78
Mycobacterium marinum 3.13
Mycobacterium abscessus 6.25
Mycobacterium bolletii 6.25
Mycobacterium massiliense 6.25
Mycobacterium avium 12.5
Corynebacterium glutamicum >100
Corynebacterium diphtheriae >100
Micrococcus luteus >100
Listeria monocytogenes >100
Staphylococcus aureus >100
Bacillus subtilis >100
Enterococcus faecalis >100
Escherichia coli >100
Pseudomonas putida >100
Pseudomonas aeruginosa >100
Salmonella typhimurium >100
Candida albicans >100
1034Cytotoxicity of pyridomycin on human cell lines
To determine whether pyridomycin is cytotoxic to human cells,
the concentration-dependent cytotoxicity of the compound was
assessed on two human cell lines. Data indicated that the
amount of pyridomycin needed to kill 50% of HepG2 cells
(human hepatic cell line) or A549 cells (human lung epithelium
cell line) was 100 and 50mg/ml, respectively. Pyridomycin
therefore shows higher selectivity for M. tuberculosis compared
to the human cells tested (selectivity index >100-fold), in
agreement with a previous finding that pyridomycin shows
low toxicity in an acute murine model following 800mg/kg
intraperitoneal injection (Maeda et al, 1953).
Identification of the pyridomycin target
The strategy to identify the target and mechanism of action of
pyridomycin was to raise pyridomycin-resistant mutants and to
pinpoint the genetic mutations responsible for this phenotype,
anticipating that these mutations would be in the gene for the
drug target. Resistant mutants of strain H37Rv were selected on
solid medium containing pyridomycin at 10 MIC (3mg/ml)
and arose at a frequency of around 106. Of the 10 colonies
selected for further analysis (PYR1 to 10), nine showed no
change in the MIC to pyridomycin when re-tested by REMA,
whereas mutant PYR7 retained a near 10-fold increase in its
resistance level compared to the parent H37Rv (Fig 2). This
phenotype was stably maintained and mutant PYR7 remained
fully susceptible to isoniazid, moxifloxacin and rifampicin like
wild-type H37Rv (Fig 2).
To identify the single nucleotide polymorphisms (SNPs) or
insertion/deletions (INDELs) responsible for the pyridomycin
resistance, the genomes of both PYR7 and the parental strain
were sequenced to near completion by the Illumina protocol.
Ninety-eight percent of the reads were successfully mapped to 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.the H37Rv reference genome (Cole et al, 1998) resulting in an
average 300-fold coverage. Comparison of the PYR7 and H37Rv
assemblies revealed 63 SNPs of which 53 mapped to the
repetitive PE and PPE gene families and were therefore
discarded. Of the remaining 10 SNPs, nine were synonymous.
The only non-synonymous mutation found was an a443g
transition in inhA resulting in replacement of the aspartic acid at
position 148 by a glycine (D148G). This missense mutation was
subsequently confirmed by conventional Sanger sequencing.
With reference to previously published structures of the
NADH-dependent enoyl-ACP reductase InhA, Asp148 was
found to be located near the NADH binding pocket (Dessen
et al, 1995; Dias et al, 2007; Molle et al, 2010; Oliveira et al, 2006;
Rozwarski et al, 1999; Vilcheze et al, 2006).
Genetic validation of InhA as the target of pyridomycin
To genetically validate InhA as the target of pyridomycin, we
evaluated whether over expression of inhA caused an increase
in resistance to the antibiotic in wild-type M. tuberculosis. For
this purpose, we transformed strain H37Rv with a plasmid
carrying the inhA gene under the control of the hsp60 promoter
(pMVinhA; Larsen et al, 2002). In Fig 2, it can be seen that
H37Rv::pMVinhA displayed a 15-fold higher MIC for pyrido-
mycin compared to the control strain H37Rv::pMV261 (from
0.31 to 5mg/ml). When the same experiment was performed
in the PYR7 background, no complementation of the resistant
phenotype was observed, indicating that the associated
mutation was dominant. Similar to the wild-type strain, we
noticed a four-fold increase in resistance in PYR7::pMVinhA
compared to the empty vector (PYR7::pMV261; from 2.5 to
10mg/ml; Fig 2). In control experiments, overexpression of
inhA also led to increased isoniazid resistance in both strains
whilst not impacting the MIC of moxifloxacin (Fig 2). Together,
these genetic data strongly suggest that InhA is the target of
pyridomycin.
To further corroborate that the D148G mutation in inhA
was indeed responsible for pyridomycin resistance, we over-
expressed this allele in H37Rv and compared its effect with that
of a well-characterized mutation associated with isoniazid
resistance, InhA (S94A) (Vilcheze et al, 2006). Results presented
in Fig 2 clearly show that, compared to overexpression of
wild-type InhA (pMVinhA), overexpression of InhA (D148G)
causes four-fold greater resistance to pyridomycin while
overexpression of InhA (S94A) conferred only two-fold
resistance. Furthermore, overexpression of InhA (D148G) had
no impact on the MIC for isoniazid compared to overexpression
of wild type InhA, while, as expected, overexpressing InhA
(S94A) increased resistance around four-fold (Fig 2). None
of the mutations affected the MIC for moxifloxacin (Fig 2).
Collectively, the data prove that the D148G mutation in InhA is
responsible for resistance to pyridomycin, whilst not noticeably
affecting isoniazid activity.
In addition to isoniazid, InhA is also the target of ethionamide
and triclosan. Susceptibility studies using these compounds
on H37Rv and PYR7 indicate that both strains are equally
sensitive with MICs of 2.0 and 12.5mg/ml, respectively. This
lack of cross-resistance indicates that D148G in InhA is likelyEMBO Mol Med (2012) 4, 1032–1042
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Figure 2. Genetic validation of InhA as the target of pyridomycin.
A-C. The compound susceptibility of wild-type H37Rv transformed with the control vector pMV261 (filled squares), pMVinhA (open squares), pMVinhA (S94A)
(open triangle) or pMVinhA (D148G) (open circle) to: (A) moxifloxacin, (B) isoniazid or (C) pyridomycin.
D-F. The compound susceptibility of pyridomycin-resistant mutant PYR7 transformed with the control vector pMV261 (filled squares), pMVinhA (open squares),
pMVinhA (S94A) (open triangle) or pMVinhA (D148G) (open circle) to: (D) moxifloxacin, (E) isoniazid or (F) pyridomycin.to have no impact on the binding to InhA of either triclosan
or the active metabolite of ethionamide, the ethionamide-NAD
adduct.
Susceptibility of isoniazid-resistant clinical isolates to
pyridomycin
Since our findings indicated that pyridomycin has the same
target as isoniazid, we investigated whether isoniazid-resistant
clinical isolates of M. tuberculosis retained susceptibility to
pyridomycin. As isoniazid is a pro-drug, clinically relevant
mutations that confer resistance are frequently found in the katG
gene encoding the catalase–peroxidase required for isoniazid
bio-activation or, less commonly, in the promoter region of
inhA, which increases expression of the protein. Of the eight
independent isoniazid-resistant clinical isolates analysed, four
had mutations in katG (S315T), three in the promoter region
of inhA [c (15)t] and one isolate carried both mutations
(Table 2). Analysis of the drug susceptibility of these isolates
confirmed that all strains carrying the katGmutation displayed a
high level of resistance to isoniazid (MIC >10mg/ml) and those
isolates carrying only the inhA promoter mutation showed
intermediate isoniazid resistance (MIC¼ 1.25mg/ml) compared
to H37Rv (0.16mg/ml; Table 2). On the contrary, isolates
carrying the katG mutations showed no resistance to pyrido-
mycin (MIC¼ 0.3–0.6mg/ml), while a mutation in the inhAEMBO Mol Med (2012) 4, 1032–1042 promoter resulted in increased pyridomycin resistance
(MIC¼ 2.5–5mg/ml; Table 2). For all clinical isolates tested,
the susceptibility to moxifloxacin was similar to wild-type
(MIC¼ 0.03–0.10mg/ml). Thus, isoniazid-resistant clinical iso-
lates carrying the inhA [c (15)t] promoter mutation displayed
cross-resistance with pyridomycin, whereas the more common
katG (S315T) isoniazid-resistant mutants retained full sensitiv-
ity to the antibiotic.
Inhibition of mycolic acid synthesis by pyridomycin
It has been elegantly demonstrated that inhibition of InhA by
isoniazid in M. tuberculosis leads to the specific depletion of
mycolic acids from the bacterial cell wall without affecting fatty
acid synthesis (Vilcheze et al, 2006). To show that pyridomycin
inhibition of InhA also results in inhibition of mycolic acid
synthesis, the mycolic and fatty acid content of M. tuberculosis
was determined in the presence and absence of pyridomycin by
radiometric thin layer chromatography (TLC). We found that
pyridomycin caused a concentration-dependent reduction of
mycolic acid synthesis (alpha-, methoxy- and keto-mycolic
acids) whilst not affecting the fatty acid content (Fig 3).
Furthermore, when performing the same experiment on PYR7,
over five-fold higher pyridomycin concentrations were needed to
inhibit mycolic acid biosynthesis consistent with the resistance
level observed. Both H37Rv and PYR7 behaved similarly when2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1035
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Table 2. Pyridomycin activity against isoniazid-resistant clinical isolates of M. tuberculosis
Isolate KatG
genotypea
inhA promoter
genotypeb
MIC (mg/ml)
Isoniazid Pyridomycin Moxifloxacin
H37Rv wt wt 0.16 0.31 0.03
1 S315T wt >10 0.63 0.03
2 S315T wt >10 0.50 0.05
3 S315T wt >10 0.50 0.05
4 S315T wt >10 0.31 0.03
5 S315T c (15)t >10 2.5 0.02
6 wt c (15)t 1.25 3.75 0.10
7 wt c (15)t 1.25 3.75 0.06
8 wt c (15)t 1.25 5 0.06
wt, wild-type.
aNumbering refers to the KatG protein sequence.
bNumbering refers to the inhA coding sequence, with þ1 corresponding to the first base of the ATG start codon.
1036the assay was repeated in the presence of isoniazid (Fig 3).
Indeed, the latter caused a concentration-dependent decrease in
the amount of mycolic acids in H37Rv and was equally effective
at inhibiting mycolic acid synthesis in PYR7. Taken together,
these data confirm that pyridomycin targets mycolic acid
synthesis and demonstrate that the InhA (D148G) enzyme in
PYR7 is much less susceptible to pyridomycin inhibition.
In vitro inhibition of InhA by pyridomycin
Inhibition of purified InhA by pyridomycin was studied to
investigate if pyridomycin alone can inhibit the enzyme or
whether in vivo bio-activation by an intracellular process is
needed. InhA, InhA (S94A) and InhA (D148G) were successfully
expressed and purified. All three enzymes were catalytically
active and oxidized NADH in the presence of the substrate
2-trans-octenoyl-CoA (OcCoA). Initial experiments determined
the NADH-binding constant (Km) and confirmed that for InhA
(S94A) it was around 6.5 times higher than for wild-type InhA
(Table 3) as reported previously (Quemard et al, 1995; Rawat
et al, 2003; Vilcheze et al, 2006). Surprisingly, we found that
the Km of InhA (D148G) for NADH was 14-fold greater than forA 
Figure 3. Inhibition of mycolic acid synthesis by pyridomycin. The fatty acid me
H37Rv and pyridomycin-resistant mutant PYR7 were evaluated by thin-layer chr
isoniazid and pyridomycin for 3 h and labeled with [1,2-14C]-acetate.
A. 14C-labeled FAMEs and MAMEs were separated by thin-layer chromatograp
B,C. Quantification of the MAME band intensity relative to the density of the FAME
(C) in H37Rv (black squares) and PYR7 (open circles).
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.wild-type InhA (Table 3) suggesting a lower affinity for NADH in
the D148G mutant. All the enzymes had a similar Vmax (around
0.52mmol/min/mg) (Table 3). Enzyme inhibition studies
showed that pyridomycin was able to inhibit both wild-type
InhA and InhA (S94A) at a similar Ki (6.5 and 4.55mM,
respectively) (Table 3). InhA (D148G) could not be inhibited at
all by pyridomycin at concentrations below 18.6mM. Statistical
analysis of inhibition of bothwild-type InhA and InhA (S94A) by
pyridomycin favours a model of competitive inhibition with
NADH as indicated by similar y-axis intercepts on Lineweaver–
Burk plots (Fig 4). These data prove that pyridomycin is the
pharmacophore that inhibits InhA, and this activity is achieved
by competitive inhibition of the NADH-binding site. Addition-
ally, these biochemical and enzymological results confirm that
InhA (D148G) is more resistant to pyridomycin while InhA
(S94A) is as susceptible as the wild-type enzyme.
Crystal structures of InhA (D148G), wild-type InhA and
InhA (S94A)
To further investigate the mode of binding of pyridomycin
to InhA at the atomic level, we crystallized and solved theB C 
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Table 3. In vitro kinetic parameters of M. tuberculosis InhA and its inhibition by pyridomycin
Wild-type InhA InhA (S94A) InhA (D148G)
NADH Km (mM) 13.5 2.3 83.59.5 19016
NADH Vmax (mmol/min/mg) 0.52 0.03 0.500.02 0.540.3
Pyridomycin Ki (mM) 6.51.2 5.00.4 No inhibition at 18.6mMstructures of wild-type InhA and InhA (S94A) mutant in
complex with NADH as previously published (Dessen et al,
1995; Dias et al, 2007; Molle et al, 2010; Oliveira et al, 2006;
Rozwarski et al, 1999; Vilcheze et al, 2006). In an attempt to
obtain crystal structures of InhA in complex with pyridomycin,
pre-crystallized InhA:NADH or InhA (S94A):NADH crystals
were soaked in a pyridomycin solution. On penetration of
pyridomicin, the crystals turned yellow but lost their ability to
diffract. This suggests that pyridomycin may induce major
conformational changes upon binding to the NADH co-factor
pocket of InhA. For control purposes, InhA:NADH crystals were
also soaked with triclosan, an inhibitor of the enoyl-ACP
substrate binding site of InhA, and the structure successfully
solved, thereby ruling out technical issues with soaking
(data not shown). As an alternative strategy to define the
pyridomycin binding site in InhA attempts were made to co-
crystallize InhA or InhA (S94A) in the presence of pyridomycin
alone or with the octenoyl CoA substrate; however, despite
testing over 1000 conditions, no diffracting crystals have been
obtained to date.
The D148G mutation leads to pyridomycin resistance as
well as to a decrease in NADH affinity (Table 3). To determine
the molecular basis for this resistance, we crystallized InhA
(D148G) in the presence or absence of NADH. As with InhA and
InhA (S94A), we obtained crystals only in presence of NADH
and solved the InhA (D148G):NADH structure to 2.54 A˚-0.05 0.00 0.05 0.10
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Figure 4. Inhibition of purified InhA by pyridomycin.
A-C. Lineweaver–Burk plot showing the competitive inhibition of wild-type InhA
NADH.
EMBO Mol Med (2012) 4, 1032–1042 (Supporting Information Table S3). By comparing the structure
of InhA (D148G):NADH with that of wild-type InhA:NADH
and InhA (S94A):NADH obtained in this study and elsewhere
(Dessen et al, 1995; Dias et al, 2007; Molle et al, 2010; Oliveira
et al, 2006; Rozwarski et al, 1999; Vilcheze et al, 2006),
we observed only one major effect, namely rotation of the
phenylalanine 149 (Phe149) side chain by 908 (Fig 5).
Otherwise, the positions of other active site residues as well
as the overall structure of the protein were identical (Supporting
Information Fig 1).
Interestingly, Phe149 in the InhA (D148G) mutant adopts the
same orientation as InhA and InhA (S94A) in complex with
INH-NADH (Dias et al, 2007; Rozwarski et al, 1999; Vilcheze
et al, 2006). Thus, in the InhA (D148G) mutant, Phe149 is
naturally placed for Pi-stacking with the INH moiety and this
explains the unchanged MIC observed for isoniazid against
wild-type InhA and the InhA (D148G) mutant in vivo (Fig 5).
Furthermore, rotation of the Phe149 side chain in the InhA
(D148G) mutant also results in opening of a water channel
allowing the addition of two water molecules in the active site as
well as increasing the distance between the nicotinamide ring of
NADH and the ring of Phe149, leading to a decrease in NADH
affinity as confirmed by kinetic studies (Fig 5). The same
structural changes most probably also explain the decreased
sensitivity of InhA (D148G) to pyridomycin compared to wild-
type as NADH and pyridomycin share a similar binding pocket.0.01 0.02
H]
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(A), InhA (S94A) (B) and InhA (D148G) (C) by pyridomycin in the presence of
2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1037
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Figure 5. Crystal structures of InhA (D148G) compared to wild-type InhA and InhA (S94A).
A. The 2fo-fc electron density map at 1 sigma of InhA (D148G):NADH structure (at 2.45 A˚) with Phe149 and NADH represented as sticks.
B. Superposition of InhA (D148G):NADH (blue) on InhA:NADH and InhA (S94A):NADH (both in green) clearly shows the D148G mutation and the resulting
908 rotation of Phe149.
C. Overlay of InhA (D148G):NADH (Blue) and InhA:NAD-INH (PDB code 1Z1D: Pink) shows that, in this case, Phe149 occupies the same position and explains why
InhA (D148G) is still sensitive to inhibition by isoniazid.
1038DISCUSSION
To inhibit or kill competing organisms, numerous microbes
produce and secrete natural products with antibiotic activity.
This rich source of chemically diverse compounds was
successfully exploited for the production of many anti-microbial
and anti-cancer drugs in the first decades of antibiotic
development but was then abandoned (Fischbach & Walsh,
2009). Since the selective pressure imparted by some antibiotics
with broad-spectrum activity may have led to naturally
occurring resistance in other bacteria that share the same
ecological niche, many potentially bio-active molecules may
have been overlooked (Smith et al, 2010). The ecological and
evolutionary forces that have shaped natural products,
particularly the selection and inhibition of vulnerable targets,
remain unknown but understanding this relationship is
important for drug discovery.
The treatment of tuberculosis is increasingly menaced by
the emergence of drug-resistant strains of M. tuberculosis and
this has led to renewed interest in finding new bactericidal
inhibitors. As in other anti-infective areas, target-based screens
have been unsuccessful prompting investigators to adopt whole
cell screening once more (Cole & Riccardi, 2011; Payne et al,
2007). Consequently, we are reinvestigating diverse natural
products for hit generation as these compounds have been
optimized by evolution as antibacterial agents. In this study,
we have used pyridomycin, a natural product with anti-
mycobacterial activity, to identify the intracellular target and
characterized its mechanism of action. Pyridomycin was first
described in 1953 (Maeda et al, 1953), shortly after the
introduction of isoniazid into clinical practice, but was then
apparently neglected. In a remarkable coincidence, we show
that, like isoniazid, pyridomycin directly targets the NADH-
dependent enoyl (ACP)-reductase InhA and causes inhibition
by competing for the NADH-binding pocket.
InhA (also known as FabI) is an essential component of the
type II fatty acid synthase system (FasII) involved in fatty acid 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.elongation and is required for mycolate production in
M. tuberculosis. The FasII system is highly conserved in bacteria
but absent from humans making it an attractive drug target
(Heath et al, 2002; McMurry et al, 1998; Vilcheze et al, 2006,
2011). Although isoniazid is certainly the most effective known
inhibitor of InhA in M. tuberculosis, it is a pro-drug requiring
activation by the KatG catalase–peroxidase to form an adduct
with NAD. Clinically significant resistance to isoniazid is mainly
attributed to loss or alteration of KatG activity. The INH-NAD
adduct acts as a slow, tightly binding competitive inhibitor of
the NADH-binding site of InhA (Rawat et al, 2003). Interestingly,
mycobacterial InhA is also targeted by the small molecules
ethionamide (Morlock et al, 2003) (also a pro-drug) and
triclosan (Parikh et al, 2000) whilst in other bacteria, FabI is
inhibited by the natural products vinaxanthone and cephalo-
chromin (Zhang & Rock, 2008). Other natural products with
broad-spectrum activity, such as thiolactomycin, cerulenin and
platensimycin, have been shown to target different components
of the FasII system in other bacteria (Zhang & Rock, 2008).
Our results suggest that pyridomycin is the most potent natural
product to inhibit FasII specifically in M. tuberculosis and
resistance arises due to remodelling of the NAD-binding site in
InhA, notably through mutation of D148G.
Pharmacologically validated drug targets are scarce in
M. tuberculosis with InhA being among the best (Lamichhane,
2011). For this reason, several attempts have been made to
develop heterocyclic inhibitors that differ from isoniazid and
ethionamide in their structure and activity. Examples include
heterocyclic boron containing compounds (diazaborine) that
react with NADþ ribose to form diazyborine-NAD adducts
that inhibit InhA similarly to INH-NAD (Baldock et al, 1996).
Triclosan analogues (Freundlich et al, 2009; Vilcheze et al, 2011)
and di-phenyl ether compounds (Sullivan et al, 2006) have been
shown to inhibit InhA with nanomalar Ki and micromolar
MICs and are both promising candidates as anti-tuberculosis
compounds. Further screening studies for Escherichia coli FabI
inhibitors have also revealed effective novel structures, many ofEMBO Mol Med (2012) 4, 1032–1042
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(Lu & Tonge, 2008; Payne et al, 2002).
It is noteworthy that, while the FasII system is present in most
bacteria, pyridomycin is a specific inhibitor of mycobacterial
species (Table 1). Amongst the mycobacteria tested here, the
InhA proteins share a high level of sequence identity (77%) and
both Asp148 and Phe149 (as well as other active site residues)
are strictly conserved, which may explain why all mycobacteria
were susceptible to the antibiotic. Additionally, other patho-
genic mycobacteria such as M. leprae and M. ulcerans also
share near identical InhA proteins (91 and 93% identity to the
M. tuberculosis ortholog, respectively) and are expected to be
susceptible to pyridomycin (Supporting Information Fig 1).
The level of sequence identity between M. tuberculosis InhA
and FabI from the different Gram-positive and Gram-negative
bacteria tested here is considerably lower, ranging from 27
to 33%. Neither Asp148 nor Phe149 are conserved in these
enzymes, which probably accounts for their pyridomycin
resistance. It is possible that through cohabitating with
producers of pyridomycin, or a related natural product, the
ancestors of these bacteria may have acquired resistance to the
antibiotic as has been proposed for arylomycin, a natural
product that inhibits signal peptidase I (Smith et al, 2010).
The increasing emergence of isoniazid resistance in clinical
isolates of M. tuberculosis is an important problem for
tuberculosis therapy and seriously compromises the effective-
ness of current treatment. In 50–95% of the cases, resistance to
isoniazid is caused by mutations in katG (Zhang & Yew, 2009).
Low-level resistance to isoniazid is also associated with
upregulation of inhA but mutations in the inhA gene itself
are much less common (8–43%) (Zhang & Yew, 2009). Our data
clearly show that pyridomycin does not require activation. This
is of particular significance because it means that pyridomycin
can effectively kill isoniazid-resistant M. tuberculosis carrying
katG mutations as demonstrated by our susceptibility testing of
isoniazid-resistant clinical isolates.
The pyridomycin resistant strain PYR7, that carries the
D148G mutation in InhA, is not cross-resistant to isoniazid and
ethionamide while, conversely, the S94A variant that displays
isoniazid resistance remains susceptible to pyridomycin (Fig 2).
This suggests that, while both pharmacophores are competitive
inhibitors of NADH-binding, they bind to the pocket in different
ways. Additionally, the lack of cross resistance with triclosan,
the scaffold for other InhA inhibitor programs, is promising
as it demonstrates that there are multiple ways of inhibiting
the same protein without cross-resistance occurring. These are
important findings for rational drug design and could lead to
the development of pyridomycin derivatives that kill multiple
mycobacteria unlike isoniazid, which is effective solely against
M. tuberculosis.MATERIALS AND METHODS
General information
Bacterial strains, culture conditions, pyridomycin production and
purification, expression and purification of proteins and details ofEMBO Mol Med (2012) 4, 1032–1042 materials are described in Supporting Information Materials and
Methods.
Determination of pyridomycin MIC
The drug susceptibility of all bacteria was determined using the
resazurin microtitre assay (REMA; Palomino et al, 2002). Briefly,
log-phase bacteria were diluted to an OD600 of 0.0001, and grown in
a 96-well plate in the presence of serial compound dilutions. After
10 generations (7 days for M. tuberculosis) bacterial viability was
determined using 10ml of resazurin (0.025% w/v), and calculated as a
percentage of resazurin turnover in the absence of compound.
Methodology for determining the minimum bactericidal activity
(MBC) and intracellular activity are described in the Supporting
Information Materials and Methods.
Isolation and characterization of pyridomycin-resistant
H37Rv clones
Pyridomycin-resistant H37Rv mutants were isolated by plating
109 CFU on solid 7H10 medium containing 3mg/ml of pyridomycin
(10MIC). Following 4 weeks of incubation (37 8C), colonies were
picked and grown in 7H9 medium without pyridomycin. Colonies
were then retested for susceptibility to pyridomycin, moxifloxicin,
isoniazid and rifampicin. Pyridomycin-resistant clone PYR7 was
selected for whole genome sequencing using Illumina technology
and reads aligned to the genome sequence of the parent H37Rv
genome to identify SNPs (protocols described in Supporting Informa-
tion Materials and Methods). The SNP in inhA was validated by
conventional Sanger sequencing using an ABI3130XL genetic analyser
(Applied Biosystems).
Determination of MIC on isoniazid-resistant clinical isolates
Nine isoniazid-resistant clinical isolates that were ‘genotyped’ using
the Line probe assay (1st line drugs, GenoType MTBDRplus) were
kindly supplied by the Centre Hospitalier Universitaire Vaudois (CHUV)
and the Hoˆpitaux Universitaires de Gene`ve (HUG). Isolates were grown
to mid log phase in liquid medium and tested for their pyridomycin,
isoniazid and moxifloxacin susceptibility by REMA.
Over-expression of inhA in H37Rv and PYR7
To genetically validate that InhA was the target of pyridomycin, the
impact of over-expressing either wild-type InhA or the mutant forms
in strains H37Rv and PYR7 was determined. Briefly, Quick change
site-directed mutagenesis was used with pMVInhA [where inhA is
expressed from the hsp60 promoter in pMV261 (Larsen et al, 2002)]
to introduce t280g or a443g mutations thus generating pMVInhA
(S94A) and pMVInhA (D148G), respectively (primers in Supporting
Information Table 1). Plasmids pMVInhA, pMVInhA (S94A) and
pMVInhA (D148G) were transformed into H37Rv and PYR7. Transfor-
mants were selected using kanamycin, then verified by colony PCR for
the presence of the kanamycin-resistance cassette before determining
their MIC for pyridomycin, isoniazid and moxifloxacin by REMA.
Inhibition of mycolic acid synthesis by pyridomycin
The inhibition of mycolic acid production by pyridomycin and
isoniazid was determined as previously described (Vilcheze et al,
2006). Briefly, early log-phase cultures of H37Rv and PYR7
(OD600¼0.3, 4ml) were treated for 3 h with isoniazid (0.1, 0.4 and2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1039
Research Article www.embomolmed.org
Pyridomycin targets InhA
The paper explained
PROBLEM:
Even today, infection with Mycobacterium tuberculosis accounts
for up to two million deaths annually. The effectiveness of
current anti-tuberculosis drugs to combat these infections is
increasingly compromised by the escalating prevalence of multi-
and extensively drug-resistant tuberculosis. For these cases, the
most effective anti-tubercular compounds such as isoniazid and
rifampicin are no longer effective and this can result in mortality
rates approaching 100% for patients with extensively drug-
resistant tuberculosis. For these reasons, it is imperative to
ensure that the pipeline of drug candidates to treat tuberculosis
is well filled.
RESULTS:
We show here that the natural product pyridomycin is a
very selective bactericidal compound against mycobacteria
including Mycobacterium tuberculosis, the causative bacterium
of tuberculosis in humans. By selecting and isolating M.
tuberculosis mutants resistant to pyridomycin and sequencing
their genome, we found that a single mutation in a gene named
inhA is responsible for the resistance. InhA is already the target
of the current frontline anti-tuberculosis agent isoniazid.
However, most interestingly, no cross resistance was observed
between pyridomycin and isoniazid, both in laboratory strains
containing mutations in InhA or in the most frequently
encountered isoniazid-resistant clinical isolates that contain
mutations in katG (a gene required to activate isoniazid).
We then present detailed genetic and biochemical studies to
confirm that pyridomycin itself inhibits InhA and that in live
bacteria, this inhibition leads to the depletion of mycolic acids,
an essential cell wall component. Finally, studies of the crystal
structure of the InhA protein and the pyridomycin-resistant
form give valuable insight into the binding pocket of
pyridomycin.
IMPACT:
Inhibition of InhA is one of the most effective means of killing
Mycobacterium tuberculosis, and this is the mechanism behind
one of the most potent anti-tubercular agents currently used:
isoniazid. The increasing emergence of multi- and extensively
drug-resistant tuberculosis (both of which are resistant to
isoniazid) means that for these cases, this target can no longer be
effectively inhibited by current therapy. Our finding that
pyridomycin kills M. tuberculosis by inhibiting InhA (even in
isoniazid-resistant clinical isolates) provides a promising basis
for the development of pyridomycin or a related agent for the
treatment of isoniazid-resistant tuberculosis.
10402mg/ml) or pyridomycin (0.4, 2, 5, and 20mg/ml) prior to labelling for
20 h with [1,2-14C] acetate (1mCi/ml; Perkin Elmer). Bacteria were
harvested and washed with double-distilled H2O to remove excess
[1,2-14C]-acetate. The bacterial pellet was then treated with 2ml of
20% tetrabutyl ammonium hydroxide overnight at 100 8C to extract
the mycolic acids from the cell wall. Mycolic acids were subsequently
methylated and extracted by incubation with an equal volume of
methylene chloride and 100ml of methyl iodide for 1 h at room
temperature with mixing. The organic phase containing the mycolic
acid methyl esters (MAMEs) was washed once with 3N HCl and once
with H2O, dried under nitrogen and resuspended in a smaller volume
of methylene chloride. Radiolabelled MAMEs were analysed by TLC.
For each condition 10,000dpm were loaded on a HPTLC Silica Gel 60
F254 plate and run three times with 95:5 v/v hexane/ethyl acetate.
The MAMEs were visualized using a TyphoonTM scanner (GE
Healthcare) and quantified with the software ImageQuantTM (GE
Healthcare).
Steady state kinetics and inhibition of InhA
Inhibition of InhA activity was investigated using InhA, InhA (S94A)
and InhA (D148G) as described previously (Dessen et al, 1995;
Quemard et al, 1995). Briefly, kinetic parameters were determined by
following NADH oxidation at 340 nm using a TECAN FL200 spectro-
photometer. All reactions were performed at 25 8C with 100nM InhA
(or mutants) in 30mM PIPES (pH 6.8), 150mM NaCl and 10%
glycerol. After addition of variable concentrations of NADH, reactions
were initiated by adding 2-trans-octenoyl-CoA (synthesized as 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.described in Supporting Information Materials and Methods) to a
final concentration of 250mM. Steady state Km for NADH was
determined by measuring enzyme kinetics at different NADH
concentrations (0–800mM). NADH Km and pyridomycin Ki were
determined by measuring enzyme kinetics with both different NADH
(wild type InhA – 10, 12.5, 16.7, 25 and 50mM, for both InhA (S94A)
and InhA (D148G) 50, 62.5, 83.3, 125, 250mM NAHD) and different
pyridomycin concentrations (0, 0.625, 1.25, 2.5, 5 and 10mg/ml).
Kinetic parameters were analysed and calculated using GraphPad
Prism 5.
Crystallization, data collection and structure determination
Crystals of the InhA:NADH complex, InhA (D148G):NADH complex and
InhA (S94A):NADH complex were obtained by vapour diffusion at
188C by equilibrating 2ml hanging drops containing a 1:1 mixture of
approximately 10mg/ml protein incubated with 5mM NADH and
crystallization buffer (10% v/v MPD and 0.1M TRIS, pH 8.0 for
InhA:NADH complex; 8% v/v MPD and 0.1M Bicine, pH 9.0 for InhA
(D148G):NADH complex; and 8% v/v MPD, 50mM Sodium Citrate,
pH 6.5 and 0.1M Hepes, pH 7.5 for InhA (S94A):NADH complex) over a
500ml reservoir of the same crystallization solution. Crystals were
stabilized by soaking briefly in a cryoprotectant solution (25% glycerol
w/v in crystallization buffer) and flash frozen in liquid nitrogen before
data collection. Diffraction data were collected on X06DA of the Swiss
Light Source (SLS, PSI, Villigen, Switzerland) and on ID29 at the
European Synchrotron Radiation Facility (ESRF, Grenoble, France). Data
were indexed, integrated and scaled with XDS (Kabsch, 2010). BothEMBO Mol Med (2012) 4, 1032–1042
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with unit cell dimensions of approximately a¼ b¼98 A˚, c¼139 A˚,
a¼b¼908 and g ¼1208, with one molecule per asymmetric unit
(Supporting Information Table 2). Phase determinations were carried
out by molecular replacement using Phaser (McCoy et al, 2007), part
of the CCP4 Suite, using as a search model the published structure
of the InhA:NADH complex from M. tuberculosis (PDB code 3OEW).
The initial molecular replacement models were manually adjusted
in COOT, part of the CCP4 Suite (Winn et al, 2011) and refined with
REFMAC5 (Murshudov et al, 1997). The refined structures were
evaluated with PROCHECK (Laskowski et al, 1996). Structure figures
were prepared with PyMOL (Molecular Graphics System, Version
1.5.0.1 Schro¨dinger, LLC). All crystallographic statistics are listed in
Supporting Information Table 2. Coordinates and structure factors
for the above complexes structures have been deposited in the
Protein Data Bank (PDB accession codes 4DRE, 4DTI and 4DQU,
respectively).Author contributions
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